• Sanofi Pasteur, of Lyon, France, the vaccines division of Sanofi SA, said clinical results published in The Lancet showed the ability of its vaccine candidate to protect against dengue fever caused by three dengue virus types. The full analysis showed vaccine efficacy to be 61.2 percent against dengue virus Type I, 81.9 percent against Type III and 90 percent against Type IV. One of the dengue virus types (serotype 2) eluded the vaccine. The study enrolled 4,002 children, ages 4 to 11, and tested the live, attenuated vaccine, given in three doses six months apart.